Funding for this research was provided by:
Newly Extended Technology Transfer Program from the Japan Science and Technology Agency (JPMJTT14N8)
Received: 3 February 2022
Accepted: 29 April 2022
First Online: 13 May 2022
: Clinical samples analyzed in this study were obtained as part of a clinical trial (JapicCTI-152998 and JapicCTI-184040). Written informed consent was obtained from all patients. This study was conducted with the approval of the Ethical Committee of Kyorin Pharmaceutical Co., Ltd. (Approval number 521). All experiments were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: KA and AK are employees of Kyorin Pharmaceutical Co., Ltd. Both authors conducted the study at their discretion and had editorial freedom concerning the manuscript. Therefore, the authors will not receive any monetary rewards from the company upon acceptance of the manuscript.